Table 1.
Baseline characteristics.
| n | % | |
|---|---|---|
| Female | 18 | 90 |
| Age (Mean ± SD, Years) | 66.7 ± 11.0 | |
| Less than 5 Years Disease Duration | 9 | 45 |
| Raynaud’s | 20 | 100 |
| ILD | 20 | 100 |
| PAH | 12 | 60 |
| Skin Thickening | 17 | 85 |
| Esophagus Involvement | 9 | 45 |
| Polyarthritis | 5 | 25 |
| ANA | 20 | 100 |
| Anti-Topoisomerase I Antibodies (Scl-70) | 19 | 95% |
| NT-proBNPLevels (Baseline, Mean ± SD, pg/mL) | 385.4 ± 517 | |
| mRSS (Baseline, Mean ± SD) | 14.4 ± 10.5 | |
| FVC (Baseline, Mean ± SD) | 93.6 ± 19.3 | |
| FEV1 (Baseline, Mean ± SD) | 89.5 ± 15.6 | |
| DLCO (B, Mean ± SD) | 58.8 ± 8.6 | |
| Ejection Fraction (Baseline, Mean ± SD) | 62.8 ± 6.4 | |
| Pulmonary Artery Pressure (Baseline, Mean ± SD) | 30.2 ± 10.5 | |
SD, standard deviation; ILD, interstitial lung disease; PAH, pulmonary artery hypertension; mRSS, Modified Rodnan Skin Score; NT-proBNP, N-terminal-pro-brain natriuretic peptide, FVC, forced vital capacity, FEV1, forced expiratory volume in one second; DLCO, diffusing capacity for carbon monoxide. Clinical and Laboratory features (ILD, PAH, skin thickening, esophagus involvement, polyarthritis, ANA, anti-topoisomerase I antibodies) are reported as dichotomous variables (yes or no).